Long-term effects of sildenapil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome;Langzeiteffekte von sildenafil bei sklerodermie-assoziierter pulmonaler hypertonie und Raynaud-syndrom

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 33, 2004, Pages 1736-1740

  Rosenkranz, S ^a,b   Caglayan, E ^a   Diet, F ^a   Karasch, T ^a   Weihrauch, J ^b   Wassermann, K ^a   Erdmann, E ^a  

^a Klinik III fur Innere Medizin   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

AGED; ARTICLE; BREATHING; CASE REPORT; DIFFUSION; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HUMAN; LUNG ARTERY PRESSURE; LUNG FIBROSIS; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCLERODERMA; SYMPTOM; TREATMENT OUTCOME;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; AGED; ATRIAL NATRIURETIC FACTOR; FEMALE; FINGERS; HUMANS; HYPERTENSION, PULMONARY; LASER-DOPPLER FLOWMETRY; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PROGNOSIS; PULMONARY WEDGE PRESSURE; RAYNAUD DISEASE; REGIONAL BLOOD FLOW; SCLERODERMA, SYSTEMIC; VASODILATOR AGENTS;

EID: 4344640508     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829025     Document Type: Article

References (16)

1. Berger R, Huelsman M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-2397
2. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-164
3. Ghofrani HA, Wiedemann R, Rose F et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900
4. Gibbs JSR, Higenbottam TW, Black C et al. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86 (Suppl 1);i1-i13
5. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1403
6. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-993
7. Leighton C. Drug treatment of scleroderma. Drugs 2001; 61: 419-427
8. Michelakis ED, Tymchak W, Noga M et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069
9. Nagaya N, Ando M, Oya H et al. Plasma brain natriuretic peptide as a non-invasive marker for efficacy of pulmonary thrombendarteriectomy. Ann Thorac Surg 2002; 74: 180-184
10. Nagaya N, Nishikimi T, Okano Y et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-208
11. Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870
12. Pfister R, Scholz M, Wielckens K, Erd mann E, Schneider CA. The value of natriuretic peptides NT-pro-BNP and BNP for the assessment of left ventricular volume and function. A prospective study of 150 patients. Dtsch Med Wochenschr 2002; 127: 2605-2609
13. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343: 1342
14. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E. Sildenafil improved pulmonary hypertension and periphera blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med 2003; 139: 871-873
15. Wakaumi M, Shiga T, Nozaki K et al. Plasma brain natriuretic peptide as a parameter to assess the efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) to treat severe primary pulmonary hypertension: A case report. Heart Vessels 2000; 15: 144-146
16. Wilkens H, Guth A, König J et al. Effect of inhaled iloprost plus sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-1222